Intellia Therapeutics (NASDAQ:NTLA) Raised to Hold at Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

NTLA has been the topic of a number of other research reports. HC Wainwright decreased their target price on shares of Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Royal Bank Of Canada reduced their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Friday, November 7th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 price objective (down previously from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. Jones Trading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Tudor Pickering set a $14.50 target price on Intellia Therapeutics in a research report on Tuesday, October 28th. Ten analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Intellia Therapeutics Trading Down 1.1%

Shares of NTLA stock opened at $10.41 on Friday. The firm has a 50-day moving average price of $9.44 and a 200 day moving average price of $12.72. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -2.44 and a beta of 2.05.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The firm’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period last year, the company earned ($1.34) EPS. As a group, research analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 53,051 shares of company stock worth $488,600 over the last three months. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently made changes to their positions in the business. CWM LLC lifted its holdings in shares of Intellia Therapeutics by 4.7% during the 3rd quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after acquiring an additional 856 shares in the last quarter. Federated Hermes Inc. raised its position in Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after purchasing an additional 927 shares during the period. Cyndeo Wealth Partners LLC raised its position in Intellia Therapeutics by 9.3% in the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after purchasing an additional 995 shares during the period. Interchange Capital Partners LLC lifted its stake in shares of Intellia Therapeutics by 9.7% during the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock worth $202,000 after purchasing an additional 1,030 shares in the last quarter. Finally, Benjamin Edwards Inc. boosted its position in shares of Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after buying an additional 1,126 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.